About US
Contact us
-
JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B eachFor Bayer's splashy reveal at the J.P. Morgan Healthcare Conference, the drugmakerraisedits peak sales projection for heart medication Kerendia and prostate cancer treatment Nubeqa to 3 billion euros2023/1/10
-
JPM23: J&J stayed in the back seat during Horizon bidding war, CEO saysIn the recent battle for rare disease expert Horizon, Johnson & Johnson largely stuck to the background, CEO Joaquin Duato explained at this year’s J.P. Morgan Healthcare Conference.2023/1/10
-
Pfizer, GSK, AbbVie and many more celebrate New Year with price hikes: reportAs many in the U.S. struggle withrising costs of living, large pharmaceutical companies have opted to ring in the New Year with price hikes. Drugmakerssuch as Pfizer, GSK, Bristol Myers S2023/1/6
-
Amgen garners wide support from pharma peers in Supreme Court patent fight with SanofiIn a closely watched patent dispute playing out at the U.S. Supreme Court, Amgen has drummed up support from fellow drugmakers large and small, plus industry associations and intellectual property gr2023/1/6
-
Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggardThis year, the FDA moved two CAR-T therapies into earlier large B-cell lymphoma (LBCL) and cleared a second cell therapy for multiple myeloma. But despite five years of collective experience making a2023/1/3
-
Tamiflu generics in short supply in latest chapter of biopharma's shortage sagaDrug shortages have become par for the course in the waning months of 2022, first plaguing the popular ADHD medicine Adderall, then the common antibiotic amoxicillin. Now, generics of Roche’s influen2023/1/3
-
After overcoming vial issue, Gilead wins FDA approval for long-acting HIV injectable SunlencaFour decades after the start of the HIV epidemic, patients whose virus has become resistant to multiple therapies have a new treatment option. Gilead Sciences' Sunlenca is nowclearedto be2022/12/30
-
Pfizer, Sanofi settle first California Zantac case slated for trial: reportIn yet another turn in the high-profile Zantac litigation, Sanofi and Pfizer agreed to settle a case set for trial in California. Bloombergfirstreportedthe news of the settlement, which c2022/12/30
-
2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning productsWith a platform that can predict which drug candidates will work in humans—and eliminate the costly and inefficient practice of testing on animals—Quris hopes to revolutionize drug development.2022/12/27
-
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delayLess than a week after the FDA reserved judgment on Merck and AstraZeneca’s Lynparza as a treatment for metastatic castration-resistant prostate cancer (mCRPC), Europe hassignedoff on its use in the2022/12/23